Most Read Articles
Dr Margaret Shi, 18 May 2020

A blood test is shown to be feasible and safe for early detection of multiple cancers in women with no current or known history of cancer, enabling early treatment with curative intent in a subset of individuals.

Christina Lau, 20 Apr 2020

Hippocampal avoidance during whole-brain radiotherapy (HA-WBRT), together with memantine, better preserves cognitive function vs WBRT plus memantine in patients with brain metastases, without compromising survival, a multi-institutional phase III trial has shown.

Natalia Reoutova, 20 May 2020

Cancer patients infected with coronavirus disease 2019 (COVID-19) appear to be at higher risk of severe outcomes, including death, but cancer type and treatment serve as better predictors, according to recent research presented at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting I.

At the time of writing, COVID-19 has spread to more than 200 countries and territories, affecting an estimated 4.5 million people and killing over 300,000. Cancer, on the other hand, is newly diagnosed in 18 million people and takes the lives of 10 million every year.

“We have invited physician scientists who are at the epicentre of the COVID-19 pandemic, taking care of patients with cancer. They gathered prospective information to understand the effects of COVID-19 on patients with cancer, are testing new treatments, and are making this knowledge available to the global research community, so we can all benefit from their experience,” said Professor Antoni Ribas from UCLA Medical Center, Los Angeles, California, US, chairperson of the COVID-19 and cancer plenary session of the meeting.

Natalia Reoutova, 28 May 2020

Fasting-mimicking diet (FMD) cycles in combination with endocrine therapy (ET) cause metabolic changes in hormone receptor (HR)-positive breast cancer patients analogous to those observed in animal models, where they are associated with anticancer activity.

Mindfulness-based stress reduction feasible in young cancer survivors

22 Mar 2020

A mindfulness-based stress reduction (MBSR) intervention is acceptable and feasible in young adults with cancer, though recruitment may be difficult, reports a new study.

The study included 126 eligible survivors who were made to accomplish a survey about acceptability and feasibility. MBSR sessions lasted for 2.5 hours and ran for 8 weeks, after which patients participated in a half-day retreat. Sessions were administered by qualified MBSR instructors.

Initially, 597 participants were identified and approached for recruitment, though only 26.5 percent (n=151) consented. Only those who underwent complete baseline measurement were included in the final sample, of whom 67 were randomized to MBSR and 59 were put on waitlist. Finally, only 48 participants enrolled into the MBSR course.

Despite difficulties in recruitment, researchers found that the intervention itself was largely feasible, with no major barriers to delivery identified. Acceptability was also high, with majority of those who declined to participate citing distance (41.5 percent) and time constraints (21.7 percent) as reasons. Only 4.9 percent expressed a lack of interest in MBSR.

Moreover, 75 percent (n=36) of those who did enrol into the programme were able to finish it, with a median MSBR attendance of 18 hours. After the course, 77.6 percent of the participants found MBSR to be very logical and 72.4 percent said that it would be “very useful in raising the quality of their wellbeing.” Majority were open to recommending the course to a friend.

In terms of efficacy, MBSR participants showed significantly greater increases in self-kindness over time compared with their waitlist comparators (p=0.031). There were also within-group improvements in sleep, intolerance of uncertainty, and post-traumatic growth relative to baseline.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Dr Margaret Shi, 18 May 2020

A blood test is shown to be feasible and safe for early detection of multiple cancers in women with no current or known history of cancer, enabling early treatment with curative intent in a subset of individuals.

Christina Lau, 20 Apr 2020

Hippocampal avoidance during whole-brain radiotherapy (HA-WBRT), together with memantine, better preserves cognitive function vs WBRT plus memantine in patients with brain metastases, without compromising survival, a multi-institutional phase III trial has shown.

Natalia Reoutova, 20 May 2020

Cancer patients infected with coronavirus disease 2019 (COVID-19) appear to be at higher risk of severe outcomes, including death, but cancer type and treatment serve as better predictors, according to recent research presented at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting I.

At the time of writing, COVID-19 has spread to more than 200 countries and territories, affecting an estimated 4.5 million people and killing over 300,000. Cancer, on the other hand, is newly diagnosed in 18 million people and takes the lives of 10 million every year.

“We have invited physician scientists who are at the epicentre of the COVID-19 pandemic, taking care of patients with cancer. They gathered prospective information to understand the effects of COVID-19 on patients with cancer, are testing new treatments, and are making this knowledge available to the global research community, so we can all benefit from their experience,” said Professor Antoni Ribas from UCLA Medical Center, Los Angeles, California, US, chairperson of the COVID-19 and cancer plenary session of the meeting.

Natalia Reoutova, 28 May 2020

Fasting-mimicking diet (FMD) cycles in combination with endocrine therapy (ET) cause metabolic changes in hormone receptor (HR)-positive breast cancer patients analogous to those observed in animal models, where they are associated with anticancer activity.